No Data
Zheshang initiates a "Buy" rating for KEYMED BIO-B (02162), with a Target Price aiming as high as 65.55 Hong Kong dollars.
Jinwu Financial News | Zheshang released a Research Report, initiating coverage on KEYMED BIO-B (02162). The company is an innovative drug enterprise deeply engaged in the fields of autoimmune diseases and oncology, with high-potential pipelines laid out in multiple sectors. Bullish on the company's leading advantages in the autoimmune field and the commercialization prospects of innovative drugs, as well as the potential for international development of the ADC and dual-antibody platforms in the future. The bank pointed out that KEYMED's pipeline mainly covers two major fields of autoimmune diseases and oncology, with 12 key candidate drugs at different stages of development, ranking among the top three in terms of IND approval in China and/or the USA for domestically produced drugs of the same category. Among them, CM310 is the first domestically produced drug to obtain approval.
Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.
The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.
The first prescription for chronic sinusitis with nasal polyps for Kangyueda (Sipuqi Baitai) has been issued nationwide, bringing a new option for disease treatment.
Chengdu, December 25, 2024 /PR Newswire/ -- On December 25, 2024, the first domestic biological agent for the treatment of chronic sinusitis with nasal polyps, Kangyueda (Supakai monoclonal antibody injection), was prescribed for the first time in the country by Director Zhang Luo at the Peking Tongren Hospital affiliated to Capital Medical University. As the first in the country and one of only two globally approved IL-4Rα antibody drugs, Kangyueda (Supakai monoclonal antibody injection) offers a new option for patients in the clinical application of treatment for chronic sinusitis with nasal polyps. Supakai monoclonal antibody is indicated for chronic sinusitis with nasal polyps in China.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Keymed Biosciences' Supplemental NDA for Rhinosinusitis Drug Gets China Nod
KEYMED BIO-B (02162.HK): The National Medical Products Administration has approved the application for the new indication of Dupilumab for the treatment of chronic sinusitis with nasal polyps.
On December 23, Gelonghui reported that KEYMED BIO-B (02162.HK) announced that the National Medical Products Administration of China ("NMPA") recently approved the new indication application for the listing of Dupilumab (anti-IL-4Rα monoclonal antibody, brand name: Kanyue Da, research and development code: CM310) for the treatment of chronic rhinosinusitis with nasal polyps. This approval is based on a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study, primarily aimed at confirming the efficacy and safety of Dupilumab injection in patients with chronic rhinosinusitis with nasal polyps. The research results
